Addex Therapeutics Ltd (FRA:APE)

Market Cap	6.93M
Revenue (ttm)	169.46K
Net Income (ttm)	-6.52M
Shares Out	n/a
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,652
Open	0.0520
Previous Close	0.0530
Day's Range	0.0520 - 0.0520
52-Week Range	0.0030 - 0.0810
Beta	n/a
RSI	51.17
Earnings Date	Apr 6, 2026

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mG...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 2
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: APE

Financial Performance

Financial numbers in CHF